Skip to content
lifestyle.harcourthealth.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Transgene S.A.
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
April 13, 2026
Availability of Transgene’s 2025 Universal Registration Document (URD)
April 9, 2026
Transgene to Participate in Upcoming Investor Meetings
April 7, 2026
Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028
March 24, 2026
←
Previous Page
1
2